GlassScriptPhysician profile
Gidgett M Bates
NPI 1265031074
$1,968.60
in general payments reported to CMS, 2019-2025
22 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $562 · 2023: $414 · 2024: $336 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $340.45 | 2021-2024 | Ingrezza |
| Abbvie INC. | $330.41 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $172.66 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $139.43 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.87 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $123.09 | 2024 | Purified Cortrophin Gel |
| Eisai INC. | $107.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $90.97 | 2021-2024 | Austedo Xr, Austedo |
| Corium, LLC | $83.21 | 2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $80.39 | 2021 | |
| Glaxosmithkline, LLC. | $69.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $52.38 | 2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $47.58 | 2025 | Wegovy |
| Ironshore Pharmaceuticals INC. | $44.88 | 2021-2023 | Jornay Pm |
| Antares Pharma, INC. | $32.37 | 2025 | Xyosted |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.72 | 2021 | |
| Collegium Pharmaceutical, INC. | $23.81 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $18.34 | 2021 | |
| Tris Pharma INC | $16.56 | 2023 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $15.95 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $15.57 | 2022 | |
| Indivior INC. | $13.54 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gidgett Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.